In: Obesity
Semaglutide liquid emulsion not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Obesity & Overweight
- Main trialPhase 4
- “This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiation through hypothalamic pathways.”In the company’s words, NCT07728383 on ClinicalTrials.gov
Other drugs for Obesity & Overweight
- CagriSemaNovo Nordisk · Filed (US)
- HRS-7535Hengrui · Kailera · Filed (China)
- RibupatideHengrui · Kailera · Filed (China)
- RetatrutideEli Lilly · Phase 3
- IN-B00009HK inno.N · Phase 3
- UBT251United Laboratories · Novo Nordisk · Phase 3
Coming up1
- May 2027Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | May 2027 | A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026